



# David D'Andrea

## Curriculum Vitae



### PERSONAL INFORMATION

Name	David D'Andrea
Work Address	Medical University of Vienna, Dept of Urology Währinger Gürtel 18-20, 1090 – Vienna (AT)
Phone	+43 40400 26150
E-Mail	david.dandrea@meduniwien.ac.at
Nationality	Italian
Date of birth	04.02.1984
	Married, 3 children
ORCID ID	0000-0003-1625-1077
Scholar h-index	29
Publications on PubMed	173
Scopus h-index	25
Publications on Scopus	168

### WORK EXPERIENCE

Nov 2019 – present	Senior Consultant in Urology at Medical University of Vienna (Austria)
Nov 2017 – Nov 2019	Consultant in Urology at Medical University of Vienna (Austria)
Feb 2016 – Oct 2017	Resident in Urology at Medical University of Vienna (Austria)
Aug 2011 – Jan 2016	Resident in Urology at Central Hospital of Bolzano (Italy)

### EDUCATION

Sept 1 <sup>st</sup> 2023	Associate Professor at Medical University of Vienna (Austria)
Oct 19 <sup>th</sup> 2021	Venia Docendi at Medical University of Vienna (Austria): Progressive development of prognostic models for response to intravesical bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer
July 2020	ÖÄK Diploma in genetic counselling
Sept 2017	Specialization in Urology and Andrology
June 3 <sup>rd</sup> 2017	Fellow of the European Board of Urology (FEBU)
March 24 <sup>th</sup> 2015	M.D. degree at Johannes Gutenberg Universität Mainz (Germany): Long-term experience in the use of botulinum toxin A for the treatment of neurogenic and non-neurogenic bladder dysfunctions
April 2004 - May 2011	Medical School at Johannes Gutenberg Universität Mainz (Germany)

### MEMBERSHIP AND SERVICES

Jul 2022 - present	Member of the Theodor-Billroth-Award and Erste Bank Research Award committee
May 2021 - present	Associate Member of the Examination Committee of the European Board of Urology

Jan 2021 - present	Full Member of the EAU Young Academic Urologists - Working Group Urothelial Cancer
2011 - present	Member of the European Association for Urology (EAU)
2016 - present	Member of the Austrian Urologic-Oncology working group
2016 - present	Member of the Austrian Association of Urology (ÖGU)
2011 - present	Member of the Italian Association of Urology (SIU)

## REVIEWER FOR SCIENTIFIC JOURNALS

European Urology  
European Urology Focus  
European Urology Oncology  
Urologic Oncology: Seminars and Original Investigations  
Prostate Cancer and Prostatic Disease  
The Journal of Urology  
Clinical Genitourinary Cancer  
Pathology – Research and practice  
World Journal of Urology  
Cancer  
British Journal of Urology International  
Minerva Urologica e Nefrologica  
Lancet Oncology

## CLINICAL TRIALS

Principal investigator	En-bloc vs Conventional Resection of Primary Bladder Tumor: Prospective randomized multicenter trial (eBLOC) Multicentric prospective T1 urinary bladder cancer (ROGUE-1) registry
Subinvestigator	SAUL MO29983; NIVOLUMAB CA209274; Bayer 19131; Bayer 17403; THOR 42756493BLC3001; POTOMAC; BMS CA-017078; CheckMate 274; Bayer 19131; Anticipate X; BMS-Nektar CA-045009; Keynote 676; CheckMate 7G8; Pure-01; FIDES-02

## TRANSLATIONAL RESEARCH

2017 – present	Immunoprofiling of T1 bladder cancer for the prediction of BCG response
2020	Association of molecular subtypes with response to BCG in T1 bladder cancer

## FUNDING AND AWARDS

Apr 2016	Massimino D'Arimento Award: Does hexaminolevulinate detect chromosomal aberrations in the false-positive bladder biopsies?
Nov 2016	Richard Übelhör Award: The role and mechanism of argon preconditioning for oxygen glucose deprivation induced cell death in human renal cells
Nov 2017	Richard Übelhör Award: Immunoprofile of pT1 bladder cancer for the prediction of BCG response
Mar 2017	Outstanding reviewer for European Urology Focus
Dec 2017	Braking Boundaries Award – Department of Urology, Medical University of Vienna
Nov 2018	Richard Übelhör Award: En-bloc vs conventional resection of primary bladder tumor: prospective randomized multicenter trial

Feb 2018	Outstanding Reviewer for European Urology Oncology
Nov 2019	Richard Übelhör Award: Differential response of luminal vs basal molecular subtype of bladder cancer to intravesical Bacillus Calmette-Guérin immunotherapy: a retrospective analysis
Dec 2019	Braking Boundaries Award – Department of Urology, Medical University of Vienna
Nov 2020	ÖGU Best Paper Award: Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle invasive bladder cancer
Nov 2020	EAU Research Foundation Grant for Castor EDC: Multicentric prospective T1 urinary bladder cancer (ROGUE-1) registry
Mar 2021	Reviewer of the Month for European Urology
June 2021	EAU Research Foundation Seeding Grant: Single post-operative dose of intravesical chemotherapy after kidney-sparing surgery for upper tract urothelial carcinoma for the prevention of intravesical recurrence: prospective randomized multicenter trial
June 2021	EAU Research Foundation Grant for Castor EDC: Single post-operative dose of intravesical chemotherapy after kidney-sparing surgery for upper tract urothelial carcinoma for the prevention of intravesical recurrence: prospective randomized multicenter trial
Nov 2021	ÖGU Best Paper Award: Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer
Dec 2021	Top Ten Reviewers of the Year for European Urology Oncology
Dec 2021	Best Researcher Award – Department of Urology, Medical University of Vienna
Mar 2022	EAU Young Academic Urologists Reviewer of the year
Sept 2023	Kardinal-Innitzer-Preis

#### BEST POSTER AND PRESENTATIONS

EAU 2021	Survival outcomes after radical cystectomy versus conservative management for clinical T1 high grade non-muscle invasive micropapillary bladder cancer: a multicenter collaboration by the European Association of Urology – Young Academic Urologists
EAU 2019	841 Association of super extended lymphadenectomy at radical cystectomy with perioperative complications
EAU 2019	PT369 Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma
EAU 2012	463 Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity – a prospective randomized double-blind study

#### TEACHING EXPERIENCE

2020 – 2021	Responsible of didactic lectures for residents program
2016 – 2017	Case based learning – 5 <sup>th</sup> semester (seminar)
2017	Sexuality, reproduction, pregnancy and birth (BL 15 - lecture)
2018	Radiologic diagnostic in urology (seminar)
2018	Urologic emergency (seminar)
2018	Physical medical examination (seminar)
2019	The clinical-practical year (Seminar)
2019	Kidney and homeostasis (BL 14 - lecture)
2021 - present	Group leader SSM 3 – Study Project

2017 - present	Development of exam questions for medical students
2017 - present	Mentoring of Students during the Clinical Practical Year
2016 - present	Mentor for graduate students
2016 - present	Examinator for graduation candidates
2023 - present	Examinator for PhD candidates

#### **BOOK CHAPTERS**

Urologic Oncology, edited by Axel S. Merseburger and Maximilian Burger  
 ISBN: 9783319431123  
 Textbook of urology, edited by Peter Nyirády  
 ISBN: 9789633313886  
 Tintinalli's Emergency Medicine 7th edition  
 ISBN:9788872875452

#### **PERSONAL SKILLS**

February 2015	DEGUM diploma in clinical ultrasound
Mother tongues	Italian and German
Other languages	English (B2), Spanish (A2), French (A1)

#### **COMMUNICATION SKILLS**

2019	WiFi Rethorik-Akademie Diploma
------	--------------------------------

## PUBLICATIONS

### Publications

En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial  
**David D'Andrea**, Francesco Soria, Rodolfo Hurle, Dmitry Enikeev, Sergey Kotov, Sophie Régnier, Evangelos Xylinas, Lukas Lusuardi, Axel Heidenreich, Chao Cai, Nicola Frego, Mark Taraktin, Maxim Ryabov, Paolo Gontero, Eva Compérat, Shahrokh F. Shariat, eBLOC Study Team

European Urology Oncology. 2023 Aug 4. doi: 10.1016/j.euo.2023.07.010. Online ahead of print.

Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.

**D'Andrea D**, Shariat SF, Soria F, DI Trapani E, Mertens LS, VAN Rhijn BW, Dinney CP, Black PC, Spiess PE, Carrion DM, Pradere B, Tonin E, Pichler R, Filippot R, Mari A, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.  
Minerva Urol Nephrol. 2023

Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.

Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A, Di Maida F, Pradere B, Mertens LS, Longoni M, Krajewski W, Del Giudice F, **D'Andrea D**, Laukhtina E, Shariat SF, Minervini A, Moschini M, Mari A, On Behalf Of European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group.  
Cancers (Basel)

Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma.

von Deimling M, **D'Andrea D**, Pradere B, Laukhtina E, Yanagisawa T, Kawada T, Majdoub M, Rajwa P, Pallauf M, Singla N, Soria F, Margulis V, Chlosta P, Karakiewicz PI, Roupret M, Teoh JY, Fisch M, Rink M, Moschini M, Lotan Y, Shariat SF.  
World J Urol. 2023

Comment on: "Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG".

Lonati C, Soria F, Pradere B, **D'Andrea D**, Laukhtina E, Mertens LS, Albinini S, Krajewski W, Afferi L, Del Giudice F, Gallioli A, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group.  
Minerva Urol Nephrol. 2023

Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer.

von Deimling M, Mertens LS, van Rhijn BWG, Lotan Y, Spiess PE, Daneshmand S, Black PC, Pallauf M, **D'Andrea D**, Moschini M, Soria F, Del Giudice F, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh JY, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz PI, Babjuk M, Gontero P, Xylinas E, Rink M, Shariat SF, Pradere B.  
Eur Urol Open Sci. 2023

Age represents the main driver of surgical decision making in patients candidate to

radical cystectomy.

Dell'Oglio P, Tappero S, Panunzio A, Antonelli A, Salvador D, Xylinas E, Alvarez-Maestro M, Hurler R, Salas RS, Colomer A, Simone G, Hendricksen K, Peroni A, Lonati C, Olivero A, Rouprêt M, Roumigué M, Soria F, Umari P, **D'Andrea D**, Terrone C, Galfano A, Moschini M, Trapani ED; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.

J Surg Oncol. 2023

Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?

Soria F, **D'Andrea D**, Barale M, Gust KM, Pisano F, Mazzoli S, De Bellis M, Rosazza M, Livoti S, Dutto D, Lillaz B, Pradere B, Moschini M, Tamandl D, Shariat SF, Gontero P; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group.

Eur Urol Open Sci. 2023

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.

Del Giudice F, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, Viscuso P, Salciccia S, Sciarra A, **D'Andrea D**, Pradere B, Moschini M, Mari A, Albisinni S, Krajewski W, Szydełko T, Małkiewicz B, Nowak Ł, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Soria F, Mori K, Tully KH, Pichler R, Ferro M, Tataru OS, Autorino R, Crivellaro S, Crocetto F, Busetto GM, Basran S, Eisenberg ML, Chung BI, De Berardinis E.

Cancers (Basel)

Comment on: "Do perioperative blood transfusions impact oncological outcomes of robot-assisted radical cystectomy with intracorporeal urinary diversion? Results from a large multi-institutional registry".

Asero V, Krajewski W, Pradere B, **D'Andrea D**, Moschini M, Soria F, Gallioli A, Basran S, Chung BI, Del Giudice F.

Minerva Urol Nephrol. 2023

Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review.

Basile G, de Angelis M, Leni R, Re C, Longoni M, Mari A, Soria F, Pradere B, Del Giudice F, Laukhtina E, **D'Andrea D**, Mori K, Krajewski W, Albisinni S, Gallioli A, Breda A, Esperto F, Briganti A, Montorsi F, Moschini M, Carando R; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.

Minerva Urol Nephrol. 2023

Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy.

von Deimling M, Schuetfort VM, **D'Andrea D**, Pradere B, Grossmann NC, Kawada T, Yanagisawa T, Majdoub M, Laukhtina E, Rajwa P, Quhal F, Mostafaei H, Fajkovic H, Teoh JY, Moschini M, Karakiewicz PI, Fisch M, Rink M, Shariat SF.

Clin Genitourin Cancer. 2023

En-bloc resection of non-muscle invasive bladder cancer: does it really make a difference?

Tonin E, Shariat SF, Schiavina R, Brunocilla E, **D'Andrea D**.

Curr Opin Urol. 2023

Sex Remains Negative Prognostic Factor in Contemporary Cohort of High-Risk Non-Muscle-Invasive Bladder Cancer.

Bilski K, Kozikowski M, Skrzypczyk MA, Dobruch A, Hendricksen K, **D'Andrea D**, Czech AK, Dobruch J.

Cancers (Basel)

Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study.

Pallauf M, **D'Andrea D**, König F, Laukhtina E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian SA, Potretzke AM, Mari A, Roumiguié M, Antonelli A, Bianchi A, Khene ZE, Sfakianos JP, Jamil M, Boormans JL, Raman JD, Grossmann NC, Breda A, Heidenreich A, Del Giudice F, Singla N, Shariat SF, Pradere B. J Urol. 2023

Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy.

Katayama S, Pradere B, Grossman NC, Potretzke AM, Boorjian SA, Ghoreifi A, Daneshmand S, Djaladat H, Sfakianos JP, Mari A, Khene ZE, **D'Andrea D**, Hayakawa N, Breda A, Fontana M, Fujita K, Antonelli A, van Doeveren T, Steinbach C, Mori K, Laukhtina E, Rouprêt M, Margulis V, Karakiewicz PI, Araki M, Compérat E, Nasu Y, Shariat SF.

Int J Urol. 2023

Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy.

Claps F, Mir MC, van Rhijn BWG, Mazzon G, Soria F, **D'Andrea D**, Marra G, Boltri M, Traunero F, Massanova M, Liguori G, Dominguez-Escrig JL, Celia A, Gontero P, Shariat SF, Trombetta C, Pavan N.

Urol Oncol. 2023

Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.

Del Giudice F, **D'Andrea D**, Pradere B, Berndl F, Pallauf M, Flammia RS, Philipp D, Moschini M, Mari A, Albisinni S, Krajewski W, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Gontero P, Shariat SF, Chung BI, Soria F.

BJU Int. 2023

Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium).

Tafari A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Panunzio A, Trovato F, Catellani M, Janello LMI, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, De Cobelli O, Maiorino F, Bove P, Crocero F, Cantiello F, **D'Andrea D**, Di Cosmo F, Porpiglia F,

Ditonno P, Montanari E, Soria F, Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, Del Giudice F, Sciarra A, Galosi A, Moschini M, Shariat SF, Di Nicola M, Minervini A, Ferro M, Cerruto MA, Schips L, Pagliarulo V, Antonelli A. World J Urol. 2022

Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and perioperative outcomes.

Del Giudice F, Kim W, Li S, DE Berardinis E, Sciarra A, Salciccia S, Ferro M, Autorino R, Pandolfo SD, Crocetto F, Galfano A, Dell'oglio P, Cacciamani GE, Pradere B, Laukhtina E, **D'Andrea D**, Belladelli F, Krajewski W, Mari A, Minervini A, Gallioli A, Amparore D, Checcucci E, Fiori C, Porpiglia F, Morgantini L, Crivellaro S, Chung BI. Minerva Urol Nephrol. 2023

Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.

Laukhtina E, Moschini M, Krajewski W, Teoh JY, Ploussard G, Soria F, Roghmann F, Muenker MA, Roumiguie M, Alvarez-Maestro M, Misrai V, Antonelli A, Tafuri A, Simone G, Mastroianni R, Zhao H, Rahota RG, **D'Andrea D**, Mori K, Albisinni S, Karakiewicz PI, Fajkovic H, Enikeev D, Montorsi F, Shariat SF, Pradere B; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. BJU Int. 2023

Online Crowdfunding for Urologic Cancer Care.

Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Mostafaei H, Krajewski W, **D'Andrea D**, Małkiewicz B, Paradysz A, Ploussard G, Moschini M, Breyer BN, Pradere B, Shariat SF, Leapman MS. Cancers (Basel). 2022

Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.

Mori K, Yanagisawa T, Katayama S, Laukhtina E, Pradere B, Mostafaei H, Quhal F, Rajwa P, Moschini M, Soria F, **D'andrea D**, Abufaraj M, Albisinni S, Krajewski W, Fukuokaya W, Miki J, Kimura T, Egawa S, Teoh JY, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). World J Urol. 2023

Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.

Krajewski W, Aumatell J, Subiela JD, Nowak Ł, Tukiendorf A, Moschini M, Basile G, Poletajew S, Małkiewicz B, Giudice FD, Maggi M, Chung BI, Cimadamore A, Galosi AB, Fave RFD, **D'Andrea D**, Shariat SF, Hornak J, Babjuk M, Chorbińska J, Teoh JY, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Panunzio A, Alvarez-Maestro M, Simone G, Mastroianni R, Łaskiewicz J, Lonati C, Zamboni S, Simeone C, Niedziela Ł, Candela L, Macek P, Contieri R, Hidalgo BG, Rivas JG, Sosnowski R, Mori K, Mir C, Soria F, González-Padilla DA, Faba ÒR, Palou J, Ploussard G, Rajwa P, Hałoń A, Laukhtina E, Pradere B, Tully K, Burgos FJ, Cidre MÁJ, Szydełko T; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Urol Oncol. 2022



A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery.

Pallauf M, König F, **D'Andrea D**, Laukhtina E, Mostafaei H, Motlagh RS, Quhal F, Aydh A, Yanagisawa T, Kawada T, Rajwa P, Lusuardi L, Soria F, Karakiewicz PI, Rouprêt M, Rink M, Lotan Y, Margulis V, Singla N, Xylinas E, Shariat SF, Pradere B. *Front Oncol.* 2022

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.

**D'Andrea D**, Shariat SF, Soria F, Mari A, Mertens LS, Di Trapani E, Carrion DM, Pradere B, Pichler R, Filippot R, Grisay G, Del Giudice F, Laukhtina E, Paulnsteiner D, Krajewski W, Vallet S, Maggi M, De Berardinis E, Álvarez-Maestro M, Brönimann S, Di Maida F, van Rhijn BWG, Hendricksen K, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. *Eur Urol Open Sci.* 2022

Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States.

Del Giudice F, Huang J, Li S, Sorensen S, Enemchukwu E, Maggi M, Salciccia S, Ferro M, Crocetto F, Pandolfo SD, Autorino R, Krajewski W, Crivellaro S, Cacciamani GE, Bologna E, Asero V, Scornajenghi C, Moschini M, **D'Andrea D**, Brown DR, Chung BI. *Prostate Cancer Prostatic Dis.* 2022

Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.

Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A, Minervini A, Tellini R, Campi R, Schulz GB, Black PC, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Mondini F, Simeone C, Antonelli A, Tafuri A, Krajewski W, Matkiewicz B, Xylinas E, Soria F, Sanchez Salas R, Arora A, Cathelineau X, Hendricksen K, Ammiwala M, Borghesi M, Chierigo F, Teoh JY, Mattei A, Albisinni S, Roghmann F, Roumiguié M, Bajjeot AS, Maier E, Aziz A, Hurle R, Contieri R, Pradere B, Carando R, Poyet C, Alvarez-Maestro M, **D'Andrea D**, Shariat SF, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. *Eur Urol Oncol.* 2022

Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.

Laukhtina E, Boehm A, Peyronnet B, Bravi CA, Batista Da Costa J, Soria F, **D'Andrea D**, Rajwa P, Quhal F, Yanagisawa T, König F, Mostafaei H, Enikeev D, Ingels A, Verhoest G, D'Hondt F, Mottrie A, Joniau S, Van Poppel H, de la Taille A, Bensalah K, Bruyère F, Shariat SF, Pradere B. *World J Urol.* 2022

Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.

Laukhtina E, Hassler MR, Pradere B, Yanagisawa T, Quhal F, Rajwa P, Sari Motlagh R, König F, Pallauf M, Kawada T, Mostafaei H, **D'Andrea D**, Enikeev D, Shariat SF. *Eur Urol Focus.* 2022

Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy.

Arora A, Zugail AS, Pugliesi F, Cathelineau X, Macek P, Barbé Y, Karnes RJ, Ahmed M, Di

Trapani E, Soria F, Alvarez-Maestro M, Montorsi F, Briganti A, Necchi A, Pradere B, **D'Andrea D**, Krajewski W, Roumiguié M, Bajeot AS, Hurler R, Contieri R, Carando R, Teoh JY, Roupert M, Benamran D, Ploussard G, Mir MC, Sanchez-Salas R, Moschini M. *World J Urol.* 2022

HUS1 as a Potential Therapeutic Target in Urothelial Cancer.

Lindner AK, Furlan T, Orme JJ, Tulchiner G, Staudacher N, **D'Andrea D**, Culig Z, Pichler R.

*J Clin Med.* 2022

Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics.

König F, Grossmann NC, Soria F, **D'Andrea D**, Juvet T, Potretzke A, Djaladat H, Ghoreifi A, Kikuchi E, Hayakawa N, Mari A, Khene ZE, Fujita K, Raman JD, Breda A, Fontana M, Sfakianos JP, Pfail JL, Laukhtina E, Rajwa P, Pallauf M, Cacciamani GE, van Doeveren T, Boormans JL, Antonelli A, Jamil M, Abdollah F, Budzyn J, Ploussard G, Heidenreich A, Daneshmand S, Boorjian SA, Roupert M, Rink M, Shariat SF, Pradere B.

*Cancers (Basel).* 2022

Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.

Mori K, Schuetthfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JY, Resch I, Fajkovic H, Moschini M, **D'Andrea D**, Abufaraj M, Karakiewicz PI, Lotan Y, Scherr D, Egawa S, Compérat E, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

*Ann Surg Oncol.* 2022

The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations.

Del Giudice F, Flammia RS, Pecoraro M, Moschini M, **D'Andrea D**, Messina E, Pisciotto LM, De Berardinis E, Sciarra A, Panebianco V.

*World J Urol.* 2022

Comment on: Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: comparison with standard management in a high-volume center and Trifecta proposal.

Del Giudice F, Chung BI, Moschini M, Mari A, **D'Andrea D**, Soria F, Krajewski W, Gallioli A, DE Berardinis E, Maggi M; EAU-YAU Urothelial Cancer Working Party.

*Minerva Urol Nephrol.* 2022

Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy.

Moll M, **D'Andrea D**, Zaharie A, Grubmüller B, Paschen C, Zehetmayer S, Shariat SF, Widder J, Goldner G.

*Strahlenther Onkol.* 2022

Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis.

Mori K, Schuetthfort VM, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P,

Mostafaei H, Sari Motlagh R, Quhal F, Moschini M, Soria F, Teoh JYC, **D'Andrea D**, Abufaraj M, Albisinni S, Krajewski W, Egawa S, Karakiewicz PI, Rink M, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

Eur Urol Focus. 2022

Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?

Cimadamore A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, **D'Andrea D**, Shariat SF, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.

Urol Oncol. 2022

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.

Del Giudice F, Flammia RS, Chung BI, Moschini M, Pradere B, Mari A, Soria F, Albisinni S, Krajewski W, Szydełko T, Laukhtina E, **D'Andrea D**, Gallioli A, Mertens LS, Maggi M, Sciarra A, Salciccia S, Ferro M, Scornajenghi CM, Asero V, Cattarino S, De Angelis M, Cacciamani GE, Autorino R, Pandolfo SD, Falagarino UG, D'Altilia N, Mancini V, Chirico M, Cinelli F, Bettocchi C, Cormio L, Carrieri G, De Berardinis E, Busetto GM, On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party.

Cancers (Basel). 2022

Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.

Grossmann NC, Pradere B, **D'Andrea D**, Schuetthfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas E, Margulis V, Moschini M, Abufaraj M, Bandini M, Lonati C, Nyirady P, Karakiewicz PI, Fajkovic H, Shariat SF.

Clin Genitourin Cancer. 2022

Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs.

Del Giudice F, van Uem S, Li S, Vilson FL, Sciarra A, Salciccia S, Busetto GM, Maggi M, Tiberia L, Viscuso P, Canale V, Panebianco V, Pecoraro M, Ferro M, Moschini M, Krajewski W, **D'Andrea D**, Cacciamani GE, Mari A, Soria F, Porpiglia F, Fiori C, Amparore D, Checcucci E, Autorino R, De Berardinis E, Chung BI.

Clin Genitourin Cancer. 2022

Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration.

Lonati C, Baumeister P, Afferi L, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi F, Briganti A, Colombo R, Tafuri A, Antonelli A, Cerruto MA, Rouprêt M, Masson-Lecomte A, Laukhtina E, **D'Andrea D**, Shariat SF,

Soria F, Marra G, Gontero P, Contieri R, Hurle R, Valiquette AS, Mir MC, Zamboni S, Simeone C, Klatte T, Teoh JY, Yoshida S, Fujii Y, Carando R, Schulz GB, Mordasini L, Mattei A, Moschini M; European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.  
Eur Urol Focus. 2021

The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy.

Martini A, Lonati C, Montorsi F, Briganti A, Colombo R, Necchi A, Simeone C, Zamboni S, Afferi L, Mattei A, Carando R, Ploussard G, Soria F, Marra G, Rouprêt M, Xylinas E, Pradere B, Abufaraj M, **D'Andrea D**, Shariat SF, Moschini M.  
Clin Genitourin Cancer. 2021

Ischemic priapism in a 12-year old patient associated with coronavirus disease 2019 (COVID-19): a case report.

Brönimann S, Talhammer F, Springer A, Tonnhofer U, Shariat SF, **D'Andrea D**.  
Urology. 2022

En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology.

Yanagisawa T, Mori K, Motlagh RS, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, **D'Andrea D**, Compérat E, Miki J, Kimura T, Egawa S, Shariat SF.  
J Urol. 2022

Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?

Del Giudice F, **D'Andrea D**, Mari A, Soria F, Krajewski W, Moschini M; YAU Urothelial Working Group.  
Minerva Urol Nephrol. 2021  
IF 3.720

Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations.

Laukhtina E, Lemberger U, Bruchbacher A, Ilijazi D, Korn S, Berndl F, **D'Andrea D**, Susani M, Enikeev D, Compérat E, Shariat SF, Hassler MR.  
J Pers Med. 2021

Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature.

Gust KM, Resch I, **D'Andrea D**, Shariat SF.  
Transl Androl Urol. 2021

Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria.

Tulchiner G, Staudacher N, Fritz J, Hackl M, Pichler M, Seles M, Shariat SF, **D'Andrea D**, Gust K, Albrecht W, Grubmüller K, Madersbacher S, Graf S, Lusuardi L, Augustin H, Berger A, Loidl W, Horninger W, Pichler R.  
Cancers. 2021  
IF 6.639

Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.

Laukhtina E, Shim SR, Mori K, **D'Andrea D**, Soria F, Rajwa P, Mostafaei H, Comp rat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.

Eur Urol Oncol. 2021

Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.

Laukhtina E, Schuettfort VM, **D'Andrea D**, Pradere B, Quhal F, Mori K, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Karakiewicz PI, Schmidinger M, Fajkovic H, Enikeev D, Shariat SF.

World J Urol. 2021

IF 4.226

Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.

Laukhtina E, Schuettfort VM, **D'Andrea D**, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Comp rat E, Nyirady P, Rink M, Enikeev D, Shariat SF.

Mol Carcinog. 2021

IF 4.784

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.

**D'Andrea D**, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carri n DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF.

J Urol. 2021

IF 7.45

Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Gu rin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration.

Lonati C, Baumeister P, Afferi L, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi F, Briganti A, Colombo R, Tafuri A, Antonelli A, Cerruto MA, Roupr t M, Masson-Lecomte A, Laukhtina E, **D'Andrea D**, Shariat SF, Soria F, Marra G, Gontero P, Contieri R, Hurle R, Valiquette AS, Mir MC, Zamboni S, Simeone C, Klatter T, Teoh JY, Yoshida S, Fujii Y, Carando R, Schulz GB, Mordasini L, Mattei A, Moschini M; European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.

Eur Urol Focus. 2021

IF 3.729

Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.

**D'Andrea D**, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS,

Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF.

World J Urol. 2021

IF 4.226

Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.

Laukhtina E, Mori K, **D'Andrea D**, Moschini M, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

Urol Oncol. 2021

IF 3.498

Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy.

Aydh A, Mori K, **D'Andrea D**, Motlagh RS, Abufaraj M, Pradere B, Mostafaei H, Laukhtina E, Quhal F, Karakiewicz PI, Luzzago S, Briganti A, Trinh QD, Parizi MK, Tilki D, Enikeev DV, Shariat SF.

Int J Clin Oncol. 2021

IF 3.402

Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes After Radical Cystectomy.

Schuetfort VM, Pradere B, **D'Andrea D**, Grossmann NC, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Karakiewicz PI, Motlagh RS, Katayama S, Lotan Y, Scherr D, Abufaraj M, Fajkovic H, Comp erat E, Enikeev D, Shariat SF.

J Urol. 2021

IF 7.45

Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.

Mori K, Pradere B, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuetfort VM, **D'Andrea D**, Egawa S, Bensalah K, Schmidinger M, Powles T, Shariat SF.

Cancer Treat Rev. 2021

IF 12.111

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer.

Katayama S, Mori K, Pradere B, Laukhtina E, Schuetfort VM, Quhal F, Motlagh RS, Mostafaei H, Grossmann NC, Rajwa P, Moschini M, Mathieu R, Abufaraj M, **D'Andrea D**, Comp erat E, Haydter M, Egawa S, Nasu Y, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

World J Urol. 2021

IF 4.226

Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. Laukhtina E, Rajwa P, Mori K, Moschini M, **D'Andrea D**, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, Shariat SF, Pradere B; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group (EAU YAU).

Eur Urol Focus. 2021

IF 3.729

Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer.

Rajwa P, Schuettfort VM, **D'Andrea D**, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Huebner N, Aulitzky A, Mun DH, Briganti A, Karakiewicz PI, Fajkovic H, Shariat SF.

Urol Oncol. 2021

IF 3.498

Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder.

Schuettfort VM, Gust K, **D'Andrea D**, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, Shariat SF.

Minerva Urol Nephrol. 2021

IF 3.720

Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.

Pones M, **D'Andrea D**, Mori K, Abufraj M, Moschini M, Comperat E, Shariat SF.

Cancers. 2021

IF 4.207

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.

Schuettfort VM, Pradere B, Trinh QD, **D'Andrea D**, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, Shariat SF.

Cancer Immunol Immunother. 2021

IF 11.151

Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.

Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, **D'Andrea D**, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF.

Eur Urol. 2021

IF 20.096

Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.  
Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, **D'Andrea D**, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, Shariat SF, Ploussard G.  
Eur Urol. 2021  
IF 20.096

The prognostic value of sarcopenia in patients with prostate cancer: a systematic review.  
Jahrreiss V, Laukhtina E, **D'Andrea D**, Shariat SF.  
Curr Opin Urol. 2021  
IF 2.309

Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.  
Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, **D'Andrea D**, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W.  
Eur Urol Focus. 2021  
IF 3.729

Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.  
Laukhtina E, Pradere B, **D'Andrea D**, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, Shariat SF.  
Minerva Urol Nephrol. 2021  
IF 3.720

Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis.  
Moschini M, Zamboni S, Afferi L, Pradere B, Abufaraj M, Soria F, **D'Andrea D**, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, Briganti A, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, Shariat SF, Xylinas E, Baumeister P.  
Arab J Urol. 2020  
IF 2.65

Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.  
Laukhtina E, Pradere B, **D'Andrea D**, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Motlagh RS, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, Shariat SF.  
Transl Androl Urol. 2021  
IF 3.15



Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer.

**D'Andrea D**, Soria F, Grotenhuis AJ, Cha EK, Malats N, Di Stasi S, Joniau S, Cai T, van Rhijn BWG, Irani J, Karnes J, Varkarakis J, Baniel J, Palou J, Babjuk M, Spahn M, Ardelt P, Colombo R, Serretta V, Dalbagni G, Gontero P, Bartoletti R, Larré S, Malmstrom PU, Sylvester R, Shariat SF.

World J Urol. 2021

IF 4.226

A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.

Schuettfort VM, **D'Andrea D**, Quhal F, Mostafaei H, Laukhtina E, Mori K, König F, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, Shariat SF.

BJU Int. 2021

IF 5.588

Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration.

Mori K, Resch I, Miura N, Laukhtina E, Schuettfort VM, Pradere B, Katayama S, **D'Andrea D**, Kardoust Parizi M, Abufaraj M, Fukuokaya W, Collà Ruvolo C, Luzzago S, Knipper S, Palumbo C, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Egawa S, Shariat SF.

Cancer Immunol Immunother. 2021

IF 11.151

Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.

Grossmann NC, Schuettfort VM, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, Abufaraj M, Karakiewicz PI, Shariat SF, **D'Andrea D**.

Onco Targets Ther. 2021

IF 4.147

A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis.

Afferi L, Abufaraj M, Soria F, **D'Andrea D**, Xylinas E, Seisen T, Roupret M, Lonati C, De la Taille A, Peyronnet B, Laukhtina E, Pradere B, Mari A, Krajewski W, Alvarez-Maestro M, Kikuchi E, Shigeta K, Chlosta P, Montorsi F, Briganti A, Simone G, Ornaghi PI, Cerruto MA, Antonelli A, Matsumoto K, Karakiewicz PI, Mordasini L, Mattei A, Shariat SF, Moschini M.

Minerva Urol Nefrol. 2021

IF 3.720

The significance of De Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy.

Quhal F, Abufaraj M, Janisch F, Mori K, Lysenko I, Mostafaei H, **D'Andrea D**, Mathieu R,

Enikeev DV, Fajkovic H, Heidenreich A, Shariat SF.

Arab J Urol. 2020

IF 2.65

Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder.

Schuetfort VM, **D'Andrea D**, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Chlosta P, Babjuk M, Deuker M, Moschini M, Shariat SF, Pradere B.

Urol Oncol. 2020

IF 3.498

Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.

Pradere B, **D'Andrea D**, Schuetfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, Briganti A, Muilwijk T, Hendricksen K, Lotan Y, Karakiewicz P, F Shariat S; UTUC collaboration.

World J Urol. 2020

IF 4.226

Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.

Schuetfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Rink M, **D'Andrea D**, Abufaraj M, Karakiewicz PI, Shariat SF.

Turk J Urol. 2020

IF 1.053

The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC).

Foerster B, Abufaraj M, Mari A, Seisen T, Bandini M, Schweitzer D, Czech AK, Moschini M, **D'Andrea D**, Bianchi M, Hendricksen K, Rouprêt M, Briganti A, van Rhijn BWG, Chłosta P, Colin P, John H, Shariat SF.

Clin Genitourin Cancer. 2020

IF 2.872

Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer.

Moschini M, Afferi L, Gandaglia G, **D'Andrea D**, Zamboni S, Di Bona C, Mordasini L, Mattei A, Baumeister P, Martini A, Burgio G, Shariat SF, Sanchez-Salas R, Cathelineau X, Stabile A, Zaffuto E, Salonia A, Colombo R, Necchi A, Montorsi F, Briganti A, Gallina A.

Eur Urol Focus. 2020

IF 3.73

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.

Schuetfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Fisch M, **D'Andrea D**, Rink M, Gontero P, Soria F, Shariat SF.

World J Urol. 2020

IF 4.226

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

**D'Andrea D**, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, Shariat SF.

BJU Int. 2020

IF 5.588

Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.

Laukhtina E, Pradere B, **D'Andrea D**, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Kimura S, Enikeev D, Shariat SF.

Urol Oncol. 2020

IF 3.498

Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007-2018 Data.

Abufaraj M, Xu T, Cao C, Waldhoer T, Seitz C, **D'andrea D**, Siyam A, Tarawneh R, Fajkovic H, Schernhammer E, Yang L, Shariat SF.

Eur Urol Focus. 2020

IF 3.73

The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group.

Gild P, Vetterlein MW, Seiler R, Necchi A, Hendricksen K, Mertens LS, Roghmann F, Landenberg NV, Gontero P, Cumberbatch M, Dobruch J, Seisen T, Grande P, **D'Andrea D**, Anract J, Comploj E, Pycha A, Saba K, Poyet C, van Rhijn BW, Noon AP, Roupret M, Shariat SF, Fisch M, Xylinas E, Rink M.

Surg Oncol. 2020

IF 3.454

Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC).

Laukhtina E, Mostafaei H, **D'Andrea D**, Pradere B, Quhal F, Mori K, Miura N, Schuettfort VM, Sari Motlagh R, Aydh A, Abufaraj M, Karakiewicz PI, Enikeev D, Kimura S, Shariat SF.

World J Urol. 2020

IF 4.226

Primary Ta high grade bladder tumors: Determination of the risk of progression.

Quhal F, **D'Andrea D**, Soria F, Moschini M, Abufaraj M, Roupret M, Karakiewicz PI, Yang L, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Shariat SF.

Urol Oncol. 2020

IF 3.498

Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer.

Ilijazi D, Pulverer W, Ertl IE, Lemberger U, Kimura S, Abufaraj M, **D'Andrea D**, Pradere B, Bruchbacher A, Graf A, Soria F, Susani M, Haitel A, Molinaro L, Pycha A, Comploj E, Pabinger S, Weinhäusel A, Egger G, Shariat SF, Hassler MR.  
Cells. 2020  
IF 4.33

Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent.  
Zamboni S, Afferi L, Soria F, Aziz A, Abufaraj M, Poyet C, Necchi A, **D'Andrea D**, Simone G, Ferriero M, Di Trapani E, Simeone C, Antonelli A, Gallina A, Montorsi F, Briganti A, Colombo R, Gandaglia G, Mattei A, Baumeister P, Mordasini L, Hendricksen K, Voskuilen CS, Rink M, Shariat SF, Xylinas E, Moschini M.  
World J Urol. 2020  
IF 4.226

The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.  
Miura N, Mori K, Mostafaei H, Quhal F, Motlagh RS, Pradere B, Laukhtina E, **D'Andrea D**, Saika T, Shariat SF.  
J Urol. 2020  
IF 7.450

Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis.  
Miura N, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Abufaraj M, Pradere B, Aydh A, Laukhtina E, **D'Andrea D**, Saika T, Shariat SF.  
Int J Clin Oncol. 2020  
IF 3.238

The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.  
Janisch F, Hillemacher T, Fuehner C, **D'Andrea D**, Meyer CP, Klotzbücher T, Kienapfel C, Vetterlein MW, Kimura S, Abufaraj M, Dahlem R, Shariat SF, Fisch M, Rink M.  
Urol Oncol. 2020  
IF 3.498

Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review.  
Miura N, Pradere B, Mori K, Mostafaei H, Quhal F, Misrai V, **D'andrea D**, Albisinni S, Papalia R, Saika T, Scarpa RM, Shariat SF, Esperto F.  
Minerva Urol Nefrol. 2020  
IF 3.720

Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies.  
Soria F, **D'Andrea D**, Abufaraj M, Moschini M, Giordano A, Gust KM, Karakiewicz PI, Babjuk M, Gontero P, Shariat SF.  
Eur Urol Focus. 2020  
IF 3.73

The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.  
Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, **D'Andrea D**, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, Briganti A, Karakiewicz PI, Shariat SF.  
Urol Oncol. 2020  
IF 3.498

Ureteral and urethral recurrence after radical cystectomy: a systematic review.  
Carando R, Shariat SF, Moschini M, **D'Andrea D**  
Curr Opin Urol. 2020  
IF 2.309

The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).  
Janisch F, **D'Andrea D**, Iwata T, Kimura S, Abufaraj M, Enikeev D, Glybochko PV, Karakiewicz PI, Nyirady P, Fajkovic H, Haitel A, Seebacher V, Rink M, Shariat SF.  
Urol Oncol. 2020  
IF 3.498

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.  
**D'Andrea D**, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF.  
Urol Oncol. 2020  
IF 3.498

Prognostic Value of the Systemic Inflammation Modified Glasgow Prognostic Score in Patients With Upper Tract Urothelial Carcinoma (UTUC) Treated With Radical Nephroureterectomy: Results From a Large Multicenter International Collaboration  
Francesco Soria, Andrea Giordano, **David D'Andrea**, Marco Moschini, Morgan Rouprêt, Vitaly Margulis, Pierre I Karakiewicz, Alberto Briganti, Karim Bensalah, Romain Mathieu, Piotr Chlostka, Marek Babjuk, Petr V Glybochko, Dmitry V Enikeev, Mesut Remzi, Kilian Gust, Paolo Gontero, Shahrokh F Shariat  
Urol Oncol 2020  
IF 3.498

Comparative Effectiveness of Radical Cystectomy and Radiotherapy Without Chemotherapy in Frail Patients With Bladder Cancer  
**David D'Andrea**, Francesco Soria, Sonja Zehetmayer, Judith Stangl-Kremser, Bernhard Grubmüller, Mohammad Abufaraj, Kilian Gust, Shoji Kimura, Marko Babjuk, Gregor M Goldner, Shahrokh F Shariat  
Scand J Urol. 2020  
IF 1.612

Development of a Prognostic Model for Survival Time Prediction in Castration-Resistant Prostate Cancer Patients  
Judith Stangl-Kremser, Andrea Mari, Rodrigo Suarez-Ibarrola, **David D'Andrea**,

Stephan M Korn, Mario Pones, Gero Kramer, Pierre Karakiewicz, Dimitri V Enikeev, Petri V Glybochko, Alberto Briganti, Shahrokh F Shariat  
Urol Oncol. 2020  
IF 3.498

Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.  
Kimura S, Iwata T, Abufaraj M, Janisch F, **D'Andrea D**, Moschini M, Al-Rawashdeh B, Fajkovic H, Seebacher V, Egawa S, Shariat SF.  
Clin Genitourin Cancer. 2019  
IF 2.534

Second line immune checkpoint inhibition in urothelial cancer.  
Gust KM, Abufaraj M, **D'Andrea D**, Moschini M, Soria F, Shariat SF.  
Transl Androl Urol. 2019  
IF 1.38

Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.  
Kimura S, **D'Andrea D**, Iwata T, Foerster B, Janisch F, Parizi MK, Moschini M, Briganti A, Babjuk M, Chlosta P, Karakiewicz PI, Enikeev D, Rapoport LM, Seebacher V, Egawa S, Abufaraj M, Shariat SF.  
World J Urol. 2019  
IF 3.303

Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.  
**D'Andrea D**, Soria F, Abufaraj M, Pones M, Gontero P, Machado AT, Waksman R, Enikeev DV, Glybochko PV, Adonias SP, Nahas WC, Shariat SF, Chade DC.  
Clin Genitourin Cancer. 2019  
IF 2.534

En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature.  
Mori K, **D'Andrea D**, Enikeev DV, Egawa S, Shariat SF.  
Curr Opin Urol. 2020  
IF 2.152

Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.  
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, **D'Andrea D**, Berndt F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M.  
Prostate. 2019  
IF 3.241

Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?  
Soria F, **D'Andrea D**, Moschini M, Giordano A, Mazzoli S, Pizzuto G, Hurle R, Colombo R, Briganti A, Altieri V, Shariat SF, Gontero P.

Urol Oncol. 2019  
IF 2.658

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.  
Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, **D'Andrea D**, Karakiewicz PI, Shariat SF  
Urol Oncol. 2019  
IF 2.658

Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy.  
Krimphove MJ, Szymaniak J, Marchese M, Tully KH, **D'Andrea D**, Mossanen M, Lipsitz SR, Kilbridge K, Kibel AS, Kluth LA, Shariat SF, Trinh QD.  
Eur Urol Focus. 2019  
IF 2.746

Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization.  
**D'Andrea D**, Abufaraj M, Soria F, Gust K, Haitel A, Krakiewicz PI, Shariat SF.  
World J Urol. 2019  
IF 3.303

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?  
**D'Andrea D**, Gontero P, Shariat SF, Soria F.  
Transl Androl Urol. 2019  
IF 1.38

The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer.  
Soria F, Marra G, **D'Andrea D**, Gontero P, Shariat SF.  
Transl Androl Urol. 2019  
IF 1.38

Enhanced Recovery after Radical Cystectomy.  
Pozo C, Shariat SF, **D'Andrea D**, Fajkovic H, Abufaraj M.  
Curr Opin Urol. 2019  
IF 2.279

Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.  
Foerster B, **D'Andrea D**, et al.  
Urol Oncol. 2019  
IF 2.658

Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.  
**D'Andrea D**, Soria F, Zehetmayer S, et al.  
BJU Int. 2019  
IF 4.806

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?

Berg S, **D'Andrea D**, Vetterlein MW, et al.

Cancer. 2019

IF 6.162

External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.

Moschini M, Zaffuto E, Karakiewicz PI, **D'Andrea D**, et al.

Eur Urol. 2019

IF 18.728

Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.

Kimura S, **D'Andrea D**, Soria F, Foerster B, Abufaraj M, Vartolomei MD, Iwata T, Karakiewicz PI, Rink M, Gust KM, Egawa S, Shariat SF

Urol Oncol. 2019

IF 2.658

Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder.

Stangl-Kremser J, **D'Andrea D**, Vartolomei M, et al.

Urol Oncol. 2018

IF 2.661

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Senn D, Kramer G, Baltzer P, **D'Andrea D**, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Eur J Eur J Nucl Med Mol Imaging. 2018

IF 7.182

Role of serum cholinesterase in patients treated with salvage radical prostatectomy.

Vartolomei MD, **D'Andrea D**, Chade DC, et al.

Urol Oncol. 2019

IF 2.658

Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study.

Soria F, Moschini M, **D'andrea D**, et al.

Eur Urol Focus. 2018

IF 1.79

Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy.

**D'Andrea D**, Soria F, Abufaraj M, et al.

Urol Oncol. 2018

IF 2.661



- Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool  
**D'Andrea D**, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, Mari A, Soria F, Briganti A, Karakiewicz PI, Gust KM, Rouprêt M, Shariat SF.  
Urol Oncol. 2018  
IF 2.661
- Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy.  
Moschini M, Soria F, Mathieu R, Xylinas E, **D'Andrea D**, et al.  
Urol Oncol. 2018  
IF 2.661
- Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor.  
Suarez-Ibarrola R, Soria F, Abufaraj M, **D'Andrea D**, et al.  
BJU Int. 2018  
IF 4.666
- Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice?  
Bruchbacher A, Soria F, Hassler M, Shariat SF, **D'Andrea D**  
Curr Opin Urol. 2018  
IF 0.919
- Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?  
Soria F, **D'Andrea D**, Pohar K, Shariat SF, Lotan Y.  
Curr Opin Urol. 2018  
IF 0.919
- PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.  
Grubmüller B, Baltzer PA, Hartenbach S, **D'Andrea D**, et al.  
Clin Cancer Res. 2018  
IF 8.911
- Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.  
Stangl-Kremser, Mari A, **D'Andrea D**, et al.  
Urol Int. 2018  
IF 1.401
- Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.  
Kimura S, Soria F, **D'Andrea D**, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, Egawa S, Shariat SF, Gust KM.  
Clin Genitourin Cancer. 2018  
IF 2.450
- An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

Soria F, Droller MJ, Lotan Y, Gontero P, **D'Andrea D**, et al.  
World J Urol. 2018  
IF 2.761

A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens.

Mari A, Kimura S, Foerster B, Abufaraj M, **D'Andrea D**, et al.  
BJU Int. 2018  
IF 4.524

Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder

Abufaraj M, **D'Andrea D**, et al.  
World Journal of Urology 2017  
IF 2.981

Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis.

Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, **D'Andrea D**, John H, Shariat SF. JAMA Oncol. 2018  
IF 20.9

Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer.

**D'Andrea D**, Hassler MR, Abufaraj M, et al.  
Expert Rev Anticancer Ther. 2018  
IF 0.881

A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer.

Mari A, Kimura S, Foerster B, Abufaraj M, **D'Andrea D**, Gust KM, Shariat SF.  
Urol Oncol. 2018  
IF 2.661

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.

Soria F, Beleni AI, **D'Andrea D**, Resch I, Gust KM, Gontero P, Shariat SF.  
World J Urol. 2018  
IF 2.761

Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer.

Ilijazi D, Abufaraj M, Hassler MR, Ertl IE, **D'Andrea D**, Shariat SF.  
Expert Rev Mol Diagn. 2018  
IF 3.099

Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.

Özsoy M, **D'Andrea D**, Moschini M, Foerster B, Abufaraj M, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, Shariat SF.  
Urol Oncol. 2018  
IF 2.661

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.  
Mari A, **D'Andrea D**, Abufaraj M, Foerster B, Kimura S, Shariat SF.  
Transl Androl Urol. 2017  
IF 0.946

Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer.  
Mari A, Abufaraj M, Foerster B, Özsoy M, Briganti A, Rouprêt M, Karakiewicz PI, Mathieu R, **D'Andrea D**, Chade DC, Shariat SF.  
Clin Genitourin Cancer. 2018  
IF 2.45

Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.  
Abufaraj M, Shariat SF, Foerster B, Pozo C, Moschini M, **D'Andrea D**, Mathieu R, Susani M, Czech AK, Karakiewicz PI, Seebacher V.  
World J Urol. 2018  
IF 2.761

Biomarkers for immunotherapy in urological cancers  
Kilian Gust, Irene Resch, **David D'Andrea**  
Current Opinion in Urology 2017  
IF 0.949

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making  
Bernhard Grubmüller, **David D'Andrea**, et al.  
European Journal of Nuclear Medicine and Molecular Imaging 2017  
IF 7.704

Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy  
Marco Moschini, **David D'Andrea**, et al.  
Urologic Oncology: Seminars and Original Investigations 2017  
IF 3.156

ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder  
**David D'Andrea**, Marco Moschini, Francesco Soria, et al.  
Anticancer Research 2017  
IF 1.946

Caveolin-1 Expression in Upper Tract Urothelial Carcinoma  
**David D'Andrea**, Marco Moschini, Beat Foerster, et al.  
European Urology Focus 2017  
IF 0.76

Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen

Veronika Seebacher, **David D'Andrea**, et al.

PloS one 2017

IF 2.766

Genetic determinants for chemo-and radiotherapy resistance in bladder cancer

Andrea Mari, **David D'Andrea**, et al.

Translational Andrology and Urology 2017

IF 0.946

Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study

Marco Moschini, Shahrokh F Shariat, Massimo Freschi, Francesco Soria, **David D'Andrea**, et al.

Urologic Oncology 2017

IF 3.156

Prognostic role of N-cadherin expression in patients with invasive bladder cancer

Mohammad Abufaraj, Andrea Haitel, Marco Moschini, Kilian Gust, Beat Foerster, Mehmet Özsoy, **David D'Andrea**, et al.

Clinical Genitourinary Cancer 2017

IF 2.223

Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy

Marco Moschini, Shahrokh F. Shariat, Mohammad Abufaraj, Beat Foerster, **David D'Andrea**, et al.

Urologic Oncology 2017

IF 3.156

Prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle invasive bladder cancer

**D'Andrea D**, Moschini M, Gust K, Abufaraj M, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, Shariat SF.

Clinical Genitourinary Cancer 2017

IF 2.223

Characteristics and clinical significance of histologic variants of bladder cancer

M. Moschini\*, **D. D'Andrea\***, Yasin Irmak, F. Soria, E. Compérat, S. Shariat

Nature Rev Urol 2017

IF 8.089

Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy

**D. D'Andrea**, M. Moschini, K.M. Gust, et al.

Journal of Surgical Oncology 2017

IF 3.124

Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy

M. Moschini, F. Soria, M. Abufaraj, B. Foerster, **D. D'Andrea**, et al.

Clinical Genitourinary Cancer 2017

IF 2.223

Update on ablative therapies of renal tumors

**D. D'Andrea**, S.F. Shariat, T. Klatte

Curr Opin Urol 2016

IF 1.021

Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients

M. Moschini, S.F. Shariat, R. Luciano, **D. D'Andrea**, et al.

Clinical Genitourinary Cancer 2016

IF 2.572

Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Pelvis: A Case Report

**D. D'Andrea**, E. Hanspeter, C. D'Elia, T. Martini, A. Pycha

Urol Case Rep. 2016

IF 0.121